Check out this article from The New York Times. Because I'm a subscriber, you can read it through this gift link without a subscription.
Alzheimer’s Drug Slows Cognitive Decline in Key Study Biogen and Eisai reported the finding from a large late-stage clinical trial of lecanemab, a drug they are developing. https://www.nytimes.com/2022/09/27/business/alzheimers-drug-biogen-lecanemab.html?unlocked_article_code=rsZSU2JmKGGy-_Exjmzb0hw2EMcmJiJYnwt1zMbDTejar-vnrnx0fQcD2v-PMNM_UJcVnoAflP6dsRoEug0g5r9dtMCLUxH9-ds6NjY0w-GEKrFHIIjqJ14Iaey6_w0tFTT4TN7kPOskkIHKeVA63t-ksQLAuUAVKhi6_n2EXmucOinMb-tT5kfVPQyw5a7Mal4GtemM_52b1wWOXEAWXU6TM356bxYRlZfEHoz76nmCZI7PijXZSJUsw8oqOi7DhWw_ieq64o02NJrv94QCFsX9_A6v771VDrcnedpoRUmV_ZDQVeSm_bjBTRsgdL2bPwsEhpVDpuJ6AFGhXPlkgizMunPd8OMUrylq&smid=em-share -- You received this message because you are subscribed to the Google Groups "Everything List" group. To unsubscribe from this group and stop receiving emails from it, send an email to [email protected]. To view this discussion on the web visit https://groups.google.com/d/msgid/everything-list/CAJPayv1%3Doy9S18afUSgmtp9XtpGEvF%3D1AP%2B4i6VdATWRR6B7Sw%40mail.gmail.com.
